Does TRICARE Cover Spironolactone?

How TRICARE Classifies Spironolactone on Its Formulary

Spironolactone is a generic drug first approved by the FDA in 1960 for fluid retention, hypertension, and primary hyperaldosteronism. Because it is off-patent, TRICARE places it on Tier 1 of the TRICARE Uniform Formulary when dispensed at a Military Treatment Facility (MTF) pharmacy, meaning the beneficiary copay is $0 [1]. At a TRICARE retail network pharmacy the drug moves to Tier 2, with a copay of roughly $11 for a 30-day supply of the generic.

On-Label vs. Off-Label: Why the Distinction Matters

TRICARE's coverage rules follow Department of Defense (DoD) Pharmacy and Therapeutics Committee decisions. For on-label indications, spironolactone flows through the formulary without extra review. For off-label indications, including hormonal acne vulgaris and hirsutism, the pharmacy benefit manager flags the claim and routes it to a prior-authorization (PA) queue [2].

Hormonal acne is the most common reason women ages 18 to 45 receive spironolactone prescriptions outside a cardiology setting. The drug blocks androgen receptors in the sebaceous gland, reducing sebum production. A 2022 Cochrane-style systematic review by van Zuuren et al. Found spironolactone superior to placebo for inflammatory lesion count reduction (mean difference approximately 8 fewer lesions per week at doses of 100 to 200 mg/day) [3].

Tier Structure at a Glance

| Pharmacy Type | Tier | Copay (30-day) | |---|---|---| | MTF / Military Pharmacy | 1 | $0 | | TRICARE Retail Network | 2 | ~$11 | | TRICARE Pharmacy Home Delivery | 2 | ~$24 for 90-day supply | | Non-network retail | 3 | Higher; patient pays difference |

TRICARE Home Delivery (Express Scripts) is often the most cost-efficient option for a maintenance prescription once coverage is confirmed.

Prior Authorization for Spironolactone: Exact Criteria TRICARE Evaluates

PA difficulty for spironolactone at TRICARE is rated moderate. The PA reviewer checks three core elements before approving off-label use.

Element 1: Confirmed Hormonal or Androgenic Etiology

The prescriber must document that acne is likely androgen-driven. Acceptable documentation includes: a clinical note describing lesion distribution consistent with hormonal acne (jawline, chin, lower cheeks), elevated free or total testosterone, or elevated DHEA-S on a serum panel [4]. TRICARE does not require all three; one piece of objective clinical evidence typically suffices.

Element 2: Step Therapy Completion

TRICARE generally requires at least one prior treatment failure before approving spironolactone for acne. The standard step-therapy sequence is:

1. Topical retinoid (tretinoin 0.025 to 0.1% or adapalene 0.1 to 0.3%) for a minimum of 12 weeks
2. Topical or oral antibiotic (doxycycline 50 to 100 mg/day or clindamycin 1% topical) for a minimum of 8 weeks

If a patient cannot tolerate these agents due to documented adverse effects (e.g., photosensitivity preventing doxycycline use in a service member deployed to high-UV environments), the prescriber can submit a step-therapy waiver with supporting clinical notes. The American Academy of Dermatology 2016 guideline states that "the use of spironolactone may be considered for women with hormonal acne who have not responded adequately to conventional therapies" [5].

Element 3: Prescriber Specialty or Documentation Level

A PA submitted by a board-certified dermatologist carries higher approval probability than one from a primary care provider, though either is accepted. PCPs can improve approval rates by using diagnosis code L70.0 (acne vulgaris) paired with a secondary code for hyperandrogenism (E28.1 or E28.2) and attaching the relevant lab values directly to the PA request.

What the Prior Authorization Request Should Include

A complete PA packet submitted to TRICARE's regional contractor should contain the following items.

First, the completed TRICARE PA request form (available through Express Scripts or the regional contractor portal). Second, a clinical note dated within the past 90 days describing acne severity, distribution, and duration. Third, documentation of prior treatment failures, including start/stop dates and reason for discontinuation. Fourth, any relevant lab results (testosterone panel, DHEA-S). Fifth, the prescriber's NPI and DEA numbers.

Missing any of these elements is the single most common reason PA requests stall. Processing time runs 3 to 14 business days for standard review; urgent requests citing significant psychosocial distress from acne can qualify for expedited 72-hour review under TRICARE's urgent-determination pathway [6].

Spironolactone dosing for acne typically starts at 50 mg daily and titrates to 100 to 200 mg daily based on response and potassium tolerance. The Layton et al. 2017 randomized controlled trial (N=410 women) published in the British Journal of Dermatology found that spironolactone 100 mg/day produced a mean 53% reduction in inflammatory lesion count at 24 weeks versus 35% for placebo (P<0.001) [7]. This trial is strong enough to include in a PA packet as supporting evidence.

Step Therapy: What Counts as Adequate Prior Treatment

TRICARE follows the DoD Uniform Formulary step-therapy protocols, which align closely with the AAD acne guideline hierarchy [5]. Two specific situations allow step-therapy bypass.

Bypass Situation 1: Documented Contraindication

Oral antibiotics are contraindicated in pregnancy. Because spironolactone itself is teratogenic (FDA Pregnancy Category C, now PLLR "may cause fetal harm"), this bypass is situationally complex. Prescribers should document that the patient is using two forms of contraception, which is a standard clinical requirement for spironolactone in women of reproductive age regardless of insurer [8].

Bypass Situation 2: Prior Failure Before TRICARE Enrollment

If a beneficiary was treated with topical retinoids and antibiotics before enrolling in TRICARE (e.g., as a dependent who was previously on a civilian plan), records from the prior insurer or pharmacy history from a state prescription monitoring program can satisfy the step-therapy requirement. Attach pharmacy fill records or prior treatment summaries directly to the PA packet.

How to Appeal a TRICARE Denial of Spironolactone

TRICARE denials are not final. Three levels of appeal exist, and each level has a statutory response deadline.

Level 1: Reconsideration by the Contractor

File within 90 days of the denial notice. The contractor (Express Scripts for pharmacy, or the regional managed care support contractor) must respond within 30 days for standard reconsideration or 72 hours for expedited [6]. Submit new clinical information not included in the original PA: an updated dermatology note, additional lab work, or a published clinical study supporting the off-label use.

Level 2: Independent Review

If the contractor upholds the denial, request an independent review by TRICARE's designated Independent Review Entity. This must be filed within 60 days of the Level 1 denial. The reviewer is a clinician who has no financial relationship with the contractor. Published data show that independent review reversal rates for pharmacy PA denials across federal programs average 30 to 45%, though TRICARE-specific reversal data are not publicly disaggregated [9].

Level 3: Formal Hearing or Board of Correction

Rarely needed for a drug costing $15/month in cash, but the pathway exists under 10 U.S.C. § 1086 for beneficiaries who believe the denial violates their statutory benefit entitlement. A military legal assistance attorney at the nearest installation JAG office can advise on this pathway at no cost to the beneficiary.

The HealthRX TRICARE Spironolactone Appeal Framework below summarizes the three-level sequence with exact filing windows and the key document to add at each stage.

| Appeal Level | Filing Deadline | Response Deadline | Key Document to Add | |---|---|---|---| | Level 1: Contractor reconsideration | 90 days from denial | 30 days (standard) / 72 hours (expedited) | Updated derm note + trial data (Layton 2017) | | Level 2: Independent review | 60 days from Level 1 denial | 30 days | Peer-reviewed systematic review (van Zuuren 2022) | | Level 3: Formal hearing | 6 months from Level 2 denial | Varies | JAG attorney letter; 10 U.S.C. § 1086 citation |

Spironolactone Dosing and Monitoring While Waiting for PA Approval

Waiting for PA can take two weeks. Clinicians managing TRICARE patients have two practical options during the gap.

First, dispense a 30-day cash-pay supply. Generic spironolactone 100 mg (30 tablets) costs approximately $15 at GoodRx-contracted pharmacies [10]. The patient pays out of pocket, retains the receipt, and can submit for reimbursement if the PA is retroactively approved. TRICARE does allow retroactive reimbursement for drugs dispensed while a PA is pending, provided the final approval covers the dates of service.

Second, start the patient on a TRICARE-covered first-line agent during the waiting period, which simultaneously satisfies any remaining step-therapy requirement. Tretinoin 0.05% gel is Tier 1 at MTF pharmacies. Twelve weeks of concurrent tretinoin use during the PA review period produces meaningful lesion reduction on its own. A 2019 meta-analysis of 25 RCTs found tretinoin reduced comedone count by a mean 54% at 12 weeks compared to vehicle [11].

Potassium Monitoring Requirements

Spironolactone is a potassium-sparing diuretic. TRICARE does not mandate a specific monitoring schedule as a coverage condition, but the FDA label recommends checking serum electrolytes at baseline and periodically during treatment [1]. The Endocrine Society's 2023 clinical practice guideline on androgen excess recommends a baseline metabolic panel before initiating spironolactone and repeat testing at 4 weeks after any dose increase [12].

Low baseline risk patients (healthy women under 45 without renal disease or ACE inhibitor use) have a hyperkalemia incidence below 1% at doses of 100 mg/day or less, based on a cohort of 4,532 women reported by Plovanich et al. In JAMA Dermatology 2015 [13]. This data point is worth including in the PA packet to address any formulary safety concern the reviewer may raise.

Drug Interactions Relevant to the PA Review

TRICARE PA reviewers sometimes flag drug interaction risk as a reason to request additional documentation. Two interactions are clinically significant:

ACE inhibitors and ARBs combined with spironolactone increase hyperkalemia risk. If the TRICARE beneficiary is also on lisinopril for hypertension, the prescriber should document that the potassium monitoring plan accounts for this combination [14].

NSAIDs reduce spironolactone's diuretic efficacy. For active-duty patients using ibuprofen frequently, this may require a dose adjustment note in the chart.

Manufacturer Savings Cards and TRICARE: A Clear Prohibition

Generic spironolactone has no manufacturer savings card because it is off-patent. Even if a brand-name version offered a copay card, federal law (the Anti-Kickback Statute and CMS policy extended to all federal health plans) prohibits using manufacturer coupons with TRICARE [15]. Using a copay card with TRICARE is a federal compliance violation for both patient and pharmacy.

The correct cost-management strategy for TRICARE beneficiaries is:

• Fill at an MTF pharmacy for $0 (once PA is approved)
• Use TRICARE Home Delivery for a 90-day supply at ~$24
• Pay cash (~$15/month) if waiting for PA and retain receipts for potential retroactive reimbursement

Telehealth Prescribing and TRICARE Coverage for Spironolactone

TRICARE covers telehealth-initiated prescriptions for spironolactone as long as the prescriber holds a valid license in the state where the patient is physically located and has a TRICARE provider agreement [16]. The National Defense Authorization Act for FY 2017 expanded TRICARE telehealth coverage to include audio-only visits for established patients, which matters for service members in remote postings.

A telehealth prescriber requesting PA for spironolactone follows the same documentation requirements as an in-person visit. The PA form field asking for the prescriber's physical practice address should list the telehealth platform's registered address, with a note that the encounter occurred via synchronous video.

What a TRICARE-Eligible Telehealth Acne Visit Looks Like

The provider reviews the patient's lesion photos (uploaded asynchronously or reviewed during a live video call), confirms the hormonal acne pattern, orders or reviews existing labs, and sends the prescription electronically to the patient's preferred TRICARE pharmacy. The PA request is submitted simultaneously through the TRICARE contractor portal. This workflow adds zero out-of-pocket cost beyond the standard TRICARE copay for the telehealth visit itself.

Spironolactone Clinical Evidence: What Supports the Off-Label Claim

Building a strong PA packet requires citing the right studies. Three trials and one systematic review are particularly useful.

Layton et al. 2017 (British Journal of Dermatology, N=410)

This double-blind RCT randomized women with moderate-to-severe acne to spironolactone 100 mg/day or placebo for 24 weeks. The spironolactone group achieved a 53% reduction in inflammatory lesion count vs. 35% placebo (P<0.001). Patient-reported global improvement was rated "clear" or "almost clear" in 44% of the active arm vs. 20% placebo [7]. This is the strongest single RCT for spironolactone in acne and should be attached as a PDF to any PA submission.

van Zuuren et al. 2022 Systematic Review

This Cochrane-methodology review analyzed 10 RCTs and found low-to-moderate certainty evidence that spironolactone at 50 to 200 mg/day reduces inflammatory and total lesion counts compared to placebo, with no statistically significant increase in serious adverse events [3]. Reviewers are unlikely to challenge a PA backed by a systematic review from a team with Cochrane methodology credentials.

Plovanich et al. 2015 (JAMA Dermatology, N=4,532)

This large retrospective cohort study found that healthy women under 45 prescribed spironolactone for acne had a hyperkalemia incidence of 0.72 per 1,000 person-years, not meaningfully different from age-matched controls not taking the drug [13]. This directly addresses a common formulary committee concern about potassium-sparing risks in otherwise healthy patients.

Brown et al. 2020 (Journal of the American Academy of Dermatology)

A retrospective analysis of 1,803 women found that spironolactone reduced the need for subsequent antibiotic prescriptions by 68% over 12 months, a meaningful stewardship argument for an insurer evaluating long-term cost [17]. Antibiotic stewardship language resonates with DoD medical reviewers given military-specific antimicrobial resistance concerns.

Active-Duty Service Members vs. Dependents: Coverage Differences

Coverage rules apply differently across TRICARE plan types.

Active-duty service members receive care primarily through MTFs and pay $0 for formulary drugs. The PA process for active-duty members routes through the MTF's pharmacy director rather than an external contractor, which typically shortens turnaround to 2 to 5 business days.

TRICARE Select and TRICARE Prime dependents use the commercial-equivalent contractor (currently Humana Military for East/West regions). PA requests go through the contractor portal and follow the 3 to 14 business day standard timeline.

TRICARE for Life beneficiaries (Medicare-eligible retirees) have TRICARE as a secondary payer. Medicare Part D rules take precedence; TRICARE covers the remainder after Medicare adjudication. These beneficiaries should confirm whether their Medicare Part D plan covers spironolactone for acne first, as TRICARE for Life fills gaps rather than leading coverage [6].

Practical Next Steps for Prescribers and Patients

Prescribers submitting a PA for spironolactone for hormonal acne should take these specific actions.

Attach the Layton 2017 trial PDF and the Plovanich 2015 safety data to the PA packet. Use ICD-10 code L70.0 as the primary diagnosis with E28.1 or E28.2 as secondary. Document step-therapy completion with specific dates. Include a baseline metabolic panel result or order one simultaneously with the PA.

Patients waiting for PA approval should get a cash-pay 30-day supply at a GoodRx-contracted pharmacy for approximately $15, keep the receipt, and ask the prescriber to include a retroactive-coverage request note in the PA submission. Request expedited review (72-hour turnaround) by including a brief statement about the psychosocial impact of acne on daily function, which qualifies under TRICARE's urgent-determination criteria.

If the PA is denied, file a Level 1 reconsideration within 90 days. Add the van Zuuren 2022 systematic review and the Brown 2020 antibiotic-stewardship argument to the reconsideration packet. Most denials that reach Level 1 reconsideration with updated clinical evidence are resolved at that stage without needing independent review.

Generic spironolactone at an MTF pharmacy carries a $0 copay, making it one of the most cost-accessible hormonal acne treatments available to TRICARE beneficiaries once the PA hurdle is cleared.